Brokerages Set Personalis, Inc. (NASDAQ:PSNL) Price Target at $11.67

Shares of Personalis, Inc. (NASDAQ:PSNL) have received an average rating of “Hold” from the eight analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $14.25.

PSNL has been the topic of a number of recent analyst reports. Needham & Company LLC cut shares of Personalis from a “buy” rating to a “hold” rating in a research report on Monday. Morgan Stanley boosted their price target on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. BTIG Research upped their price objective on shares of Personalis from $11.00 to $16.25 and gave the stock a “buy” rating in a report on Monday. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st.

Personalis Stock Down 13.3%

PSNL stock opened at $13.34 on Tuesday. Personalis has a 52-week low of $3.84 and a 52-week high of $16.39. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -13.08 and a beta of 2.24. The business has a fifty day moving average of $11.09 and a two-hundred day moving average of $8.94.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The business had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. As a group, sell-side analysts anticipate that Personalis will post -1.07 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Aaron Tachibana sold 51,251 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at $2,620,618.94. This trade represents a 20.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction on Friday, June 26th. The shares were sold at an average price of $13.15, for a total value of $1,315,000.00. Following the completion of the sale, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,103,215.90. The trade was a 29.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,032 shares of company stock worth $5,599,929 over the last 90 days. 4.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Personalis

Several institutional investors have recently bought and sold shares of PSNL. Bank of America Corp DE increased its stake in Personalis by 85.4% during the first quarter. Bank of America Corp DE now owns 111,306 shares of the company’s stock worth $709,000 after purchasing an additional 51,273 shares during the period. Janus Henderson Group PLC purchased a new position in shares of Personalis in the first quarter valued at approximately $192,000. ADAR1 Capital Management LLC purchased a new position in shares of Personalis in the first quarter valued at approximately $159,000. Sei Investments Co. grew its holdings in shares of Personalis by 148.3% in the first quarter. Sei Investments Co. now owns 139,046 shares of the company’s stock valued at $886,000 after purchasing an additional 83,040 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Personalis by 8.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock valued at $6,791,000 after purchasing an additional 83,074 shares in the last quarter. 61.91% of the stock is owned by institutional investors and hedge funds.

More Personalis News

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: Tempus AI’s acquisition gives Personalis shareholders a defined exit price of $16.25 per share, which is above the current trading level and reflects a premium to prior prices. Article Title
• Positive Sentiment: The deal could expand Personalis’ reach through Tempus’ AI-enabled precision oncology platform, supporting longer-term strategic value for the business. Article Title
• Neutral Sentiment: BTIG raised its price target on Personalis to $16.25 and kept a buy rating, signaling analyst confidence in the valuation implied by the acquisition. Article Title
• Negative Sentiment: Multiple shareholder-rights law firms have announced investigations into whether the Tempus deal delivers a fair price, raising the possibility of legal challenges or added transaction uncertainty. Article Title
• Negative Sentiment: Needham downgraded Personalis from buy to hold, adding to a more cautious tone around the stock despite the takeover announcement. Article Title

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.